|
Comparisons (miRNA-130 family)
|
Heterogeneity test
|
Summary HR (95% CI)
|
Hypothesis test
|
Studies
|
|---|
|
Q
|
P
|
I2 (%)
|
Z
|
P
|
|---|
|
miRNA-130a
|
|
OS
|
|
Total
|
22.74
|
0.01
|
56
|
1.58 (1.21,2.06)
|
3.34
|
< 0.001
|
11
|
|
Tissue
|
21.28
|
0.01
|
62
|
1.54 (1.11,2.14)
|
2.60
|
0.009
|
9
|
|
Serum
|
1.00
|
0.32
|
0
|
1.65 (1.14,2.38)
|
2.65
|
0.008
|
2
|
|
Subgroup differences
|
0.07
|
0.79
|
0
| | | | |
|
Cancer subtypes
|
|
Gastric cancer
|
1.94
|
0.38
|
0
|
1.81 (1.34,2.45)
|
3.83
|
< 0.001
|
3
|
|
Other cancers
|
18.30
|
0.01
|
62
|
1.46 (1.01,2.08)
|
2.11
|
0.03
|
8
|
|
DFS
|
|
Total
|
24.08
|
< 0.01
|
79
|
1.35 (0.72,2.52)
|
0.93
|
0.35
|
6
|
|
Tissue
|
23.91
|
< 0.01
|
83
|
1.32 (0.52,3.40)
|
0.58
|
0.56
|
5
|
|
Serum
|
–
|
–
|
–
|
1.38 (0.99,1.91)
|
0.21
|
0.83
|
1
|
|
Subgroup differences
|
0.01
|
0.94
|
0
| | | | |
|
miRNA-130b
|
|
OS
|
|
Total
|
60.10
|
< 0.01
|
77
|
1.95 (1.47,2.59)
|
4.65
|
< 0.001
|
15
|
|
Tissue
|
44.46
|
< 0.01
|
75
|
2.01 (1.39,2.91)
|
3.71
|
< 0.001
|
12
|
|
Serum
|
15.50
|
< 0.01
|
87
|
1.96 (1.09,3.54)
|
2.23
|
0.03
|
3
|
|
Subgroup differences
|
0.01
|
0.94
|
0
| | | | |
|
Ethnicity
|
|
Asian
|
12.15
|
0.06
|
51
|
2.55 (1.77,3.69)
|
5.00
|
< 0.001
|
7
|
|
Caucasian
|
23.95
|
< 0.01
|
71
|
1.47 (1.08,1.99)
|
2.45
|
0.01
|
8
|
|
Cancer subtypes
| | | | | | | |
|
HCC
|
10.59
|
0.01
|
72
|
2.43 (1.28,4.63)
|
8.24
|
0.004
|
4
|
|
Other cancers
|
30.80
|
< 0.01
|
74
|
1.75 (1.30,2.37)
|
3.67
|
< 0.001
|
11
|
|
DFS/PFS
|
|
Total
|
7.38
|
0.12
|
46
|
1.53 (1.31,1.77)
|
5.53
|
< 0.001
|
5
|
|
Tissue
|
2.48
|
0.29
|
19
|
1.98 (1.50,2.62)
|
4.85
|
< 0.001
|
3
|
|
Serum
|
0.03
|
0.86
|
0
|
1.37 (1.15,1.64)
|
3.46
|
< 0.001
|
2
|
|
Subgroup differences
|
4.87
|
0.03
|
79.5
| | | | |
|
Cancer subtypes
|
|
HCC (DFS)
|
2.48
|
0.29
|
19
|
1.98 (1.50,2.62)
|
4.85
|
< 0.001
|
3
|
|
Other cancers
|
0.03
|
0.86
|
0
|
1.37 (1.15,1.64)
|
3.46
|
< 0.001
|
2
|
- OS, overall survival; DFS, disease free survival; PFS, progressive free survival; HCC, hepatocellular carcinoma
